首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Randomized trial to assess the efficacy of intraoperative steroid use in decreasing acute urinary retention after transperineal radioactive iodine-125 implantation for prostate cancer.
【24h】

Randomized trial to assess the efficacy of intraoperative steroid use in decreasing acute urinary retention after transperineal radioactive iodine-125 implantation for prostate cancer.

机译:评估围术期放射性碘125植入前列腺癌后术中使用类固醇激素减少急性尿acute留的疗效的随机试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Acute urinary retention is a potential complication of brachytherapy, with the literature estimating that 5% to 22% of patients require catheterization within 48 hours after implantation. In theory, postimplantation edema could be reduced by using intraoperative steroids. A prospective trial was conducted randomizing patients to a single intraoperative dose of dexamethasone versus no steroid use. METHODS: In all, 196 evaluable patients who received iodine-125 (I(125)) interstitial brachytherapy alone as definitive treatment for low-to-intermediate risk prostate cancer were randomized to receive either dexamethasone at a dose of 6 mg administered intravenously intraoperatively (Arm A) or no steroids (Arm B). All patients completed the International Prostate Symptom Score before treatment. Patients were contacted by telephone 72 to 96 hours after treatment and the need for catheterization was reported. RESULTS: Between 2003 and 2005, 99 patients received steroids on treatment Arm A and 97 patients were treated according to control Arm B. Treatment arms were balanced with respect to pretreatment characteristics. A total of 3 patients required catheterization (2 in Arm A and 1 in Arm B). The overall rate of catheterization was 1.5%, with no statistically significant difference noted between treatment arms. The 3 patients requiring catheterization had no statistical differences from other patients with respect to pretreatment characteristics, number of seedseedles used, or postimplantation computed tomography volume of the prostate. CONCLUSIONS: There was no statistically significant difference noted between treatment arms in the current study, leading the authors to conclude that intraoperative dexamethasone did not decrease the rate of catheterization required after brachytherapy. The overall rate of postimplantation catheterization in the current study was 1.5%, which is lower than reported elsewhere in the literature and in a retrospective review from the study institution.
机译:背景:急性尿retention留是近距离放射治疗的潜在并发症,据文献估计,有5%至22%的患者需要在植入后48小时内进行导尿。从理论上讲,使用术中类固醇可以减少植入后的水肿。进行了一项前瞻性试验,将患者随机接受单次术中地塞米松剂量与不使用类固醇的情况。方法:总共196例接受碘125(I(125))间质近距离放射治疗作为中低风险前列腺癌的确定性治疗方法的可评估患者,被随机分配接受术中静脉注射地塞米松6 mg的剂量(手臂A)或没有类固醇(手臂B)。所有患者在治疗前均完成了国际前列腺症状评分。治疗后72至96小时通过电话与患者联系,并报告了需要进行导管插入的情况。结果:在2003年至2005年之间,有99例患者在A组治疗中接受了类固醇激素治疗,其中97例根据对照组B进行了治疗。治疗组在治疗前特征方面保持平衡。共有3名患者需要导管插入(A组2名,B组1名)。导管插入术的总率为1.5%,治疗组之间无统计学差异。 3名需要导管插入的患者在治疗前特征,使用的种子/针的数量或植入后的前列腺X线计算机断层扫描量方面与其他患者无统计学差异。结论:在本研究中,各治疗组之间无统计学差异,导致作者得出结论,术中地塞米松不会降低近距离放射治疗后所需的导管插入率。在本研究中,植入后导管插入术的总体发生率为1.5%,低于文献中以及研究机构进行的回顾性研究中报道的其他比率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号